BioCentury | Nov 5, 2012
Finance

Investors not going A-LONG

...expenses increased 24% to $31.7M and included $2.7M in charges related to Luminex's acquisition of GenturaDx...
BioCentury | Jul 30, 2012
Analyst Picks & Changes

Analyst picks & changes

...on Luminex's favorable risk/reward profile. He noted that the proposed acquisition of molecular diagnostics company GenturaDx...
BioCentury | Jul 16, 2012
Company News

GenturaDx, Luminex deal

...Luminex will acquire molecular diagnostics company GenturaDx for $50 million in cash and up to $3...
...June 30, 2014, as well as undisclosed sales milestones. The deal gives Luminex access to GenturaDx's...
...& Simms was outside counsel. UBS advised GenturaDx and Cooley Godward Kronish was outside counsel. GenturaDx...
Items per page:
1 - 3 of 3
BioCentury | Nov 5, 2012
Finance

Investors not going A-LONG

...expenses increased 24% to $31.7M and included $2.7M in charges related to Luminex's acquisition of GenturaDx...
BioCentury | Jul 30, 2012
Analyst Picks & Changes

Analyst picks & changes

...on Luminex's favorable risk/reward profile. He noted that the proposed acquisition of molecular diagnostics company GenturaDx...
BioCentury | Jul 16, 2012
Company News

GenturaDx, Luminex deal

...Luminex will acquire molecular diagnostics company GenturaDx for $50 million in cash and up to $3...
...June 30, 2014, as well as undisclosed sales milestones. The deal gives Luminex access to GenturaDx's...
...& Simms was outside counsel. UBS advised GenturaDx and Cooley Godward Kronish was outside counsel. GenturaDx...
Items per page:
1 - 3 of 3